TenderlineUK
Procurement Intelligence
Official OCDS
Find a Tender
complete
Official procurement procedure

NHS England procurement for the supply of Pan-genotypic Direct Acting Antiviral (DAA) Hepatitis C treatments and the provision of Hepatitis C elimination initiatives

No classification published
Location not published
Published value
£160,000,000
Submission deadline 6 Feb 2026, 13:00 GMT
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: NHS England: "NHS England procurement for the supply of Pan-genotypic Direct Acting Antiviral (DAA) Hepatitis C treatments and the provision of Hepatitis C elimination initiatives". Published status: complete. Published value: £160,000,000. 1 published lot. Recorded submission deadline: 6 Feb 2026, 13:00 GMT. See the official notice for participation instructions.
Contracting AuthorityNHS EnglandScope & CategoriesNot publishedSubmission Window
Closed
6 Feb 2026, 13:00 GMT
Submission GatewayDirect notice routeLegal Basis & RegimeStandard procurementEstimated Value (exc. VAT)£160,000,000
Bidder Intelligence · Authority Profile: NHS England
Market Analytics
View Authority Profile →
Derived from OCDS awards & bid statistics
Published history for NHS England. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Requires at least 5 comparable procedures
Competition Density
22.8Bids / Report
7.7% of reports have one bid
Supplier ConcentrationModerate Concentration
Anna FreudTop vendor: 29.6% of attributable value
Payment Terms
Check noticePublished terms
Payment obligations depend on the applicable regime and contract. Consult the official documents.
Coverage: 859 active published awards; 13 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Historical Awarded Suppliers With This Authority:
Supplier NameHistoric AwardsAttributable GBP Value
Anna Freud1 win£5,862,540
Anglia Ruskin University1 win£4,809,159
NHS Shared Business Services Limited1 win£4,393,727
Pearson Professional Assessments Limited1 win£4,374,320
Timewise Foundation CIC1 win£166,667
Procedure terms
Contracting AuthorityNHS England
Procedure methodNot published
Procurement categoryNot published
Statuscomplete
Framework / DPSFramework
CompetitionNot published
Above thresholdNot published
Legal basisNot published
Tender period startsNot published
Clarification deadlineNot published
Electronic submissionNot published
Submission languagesNot published
Published7 Apr 2026, 16:16 BST
Last source update7 Apr 2026, 16:16 BST
Recurring procurementNot published
ClassificationNot published
Delivery areaLocation not published
OCIDocds-h6vhtk-05cf3b
What is being bought
Project title: NHS England procurement for the supply of Pan-genotypic Direct Acting Antiviral (DAA) Hepatitis C treatments and the provision of Hepatitis C elimination initiatives commencing 1st April 2026 Offer reference number: CM/TNS/25/5737 Period of framework: 1 April 2026 to 31 March 2028 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.
What changed
From the official release history
  1. Official notice release published
    7 Apr 2026, 16:16 BST
  2. tender value changed
    26 Feb 2026, 15:59 GMT
  3. Status changed to complete
    26 Feb 2026, 15:59 GMT
  4. Official notice release published
    26 Feb 2026, 15:59 GMT
  5. Submission deadline changed to published date
    26 Feb 2026, 15:59 GMT
  6. Official notice release published
    28 Jan 2026, 12:58 GMT
  7. Submission deadline changed to 6 Feb 2026, 13:00 GMT
    28 Jan 2026, 12:58 GMT
  8. Status changed to active
    22 Dec 2025, 16:55 GMT
  9. Official notice release published
    22 Dec 2025, 16:55 GMT
  10. Submission deadline changed to 30 Jan 2026, 13:00 GMT
    22 Dec 2025, 16:55 GMT
  11. Published value updated to £160,000,000
    17 Oct 2025, 16:37 BST
  12. Status changed to planning
    17 Oct 2025, 16:37 BST
  13. Official notice release published
    17 Oct 2025, 16:37 BST
  14. Buyer information updated
    17 Oct 2025, 16:37 BST
Lots and requirements (1)
Published by the contracting authority
  • Lot 1 · #1
    Individual lot title not published
    complete
    Published valueNot published
    The source published no individual title or description for this lot.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
Timeline
  1. Procedure published
    7 Apr 2026, 16:16 BST
  2. Submission deadline
    6 Feb 2026, 13:00 GMT
  3. Award active
    Not published · Not published
  4. Contract active
    Signed 11 Mar 2026, 00:00 GMT · £160,000,000
Commercial outcome and competition
Awards
ABBVIE LTD, GILEAD SCIENCES LTD
Not published · Not published · active
Contracts
NHS England procurement for the supply of pangenotypic Hepatitis C treatments and the provision of Hepatitis C elimination initiatives
£160,000,000 · signed 11 Mar 2026, 00:00 GMT · active
Contract period: 1 Apr 2026, 00:00 BST31 Mar 2028, 23:59 BST
Bid statisticsNo aggregate bid statistics published
Buyer and organisations in this procedure

NHS England

Contracting authority GB-PPON-PDPT-3135-BWWY
View buyer profile
  • NHS England
    buyer

    GB-PPON: PDPT-3135-BWWY
    Wellington House, 133-135 Waterloo Rd, London, UKI45, SE1 8UG, GB
  • Abbvie Ltd
    supplier

    GB-PPON: PHRQ-1133-WGCH
    Abbvie House Vanwall Business Park, Maidenhead, UKJ11, SL6 4UB, GB
  • Gilead Sciences Limited
    supplier

    GB-PPON: PPDW-8775-RCQV
    280 High Holborn, London, UKI31, WC1V 7EE, GB
Documents (1)
Official links; attachments are not copied
  • Not published

    tender
    conflictOfInterest
Related procedures (0)
No data
No related procedures published